Annual report pursuant to Section 13 and 15(d)

Stockholders' Deficit (Details Narrative)

Stockholders' Deficit (Details Narrative) - USD ($)							1 Months Ended		12 Months Ended
Stockholders' Deficit (Details Narrative) - USD ($)	Aug. 31, 2020	Jun. 30, 2020	Jun. 16, 2020	May 05, 2020	May 04, 2020	Dec. 23, 2019	Aug. 31, 2020	Sep. 30, 2017	Dec. 31, 2020	Dec. 31, 2019	Jun. 09, 2020
Common stock shares authorized									10,000,000,000	10,000,000,000
Common stock par value									$ 0.0001	$ 0.0001
Preferred stock shares authorized									5,000,000
Preferred stock par value									$ 0.01
Number of shares issued upon conversion, value									$ 1,001,000
Number of common stock issued, value									2,500
Gain on extinguishment of debt									2,041,038
Deemed dividend									$ 256,400,000	$ 123,900,000
Debt converted into shares									38,371,250
Common stock shares issued									39,648,679	964,894
Common stock shares outstanding									39,648,679	964,894
Weighted average period									6 years 3 months 29 days	7 years 3 months 29 days
March 2017 Debentures [Member]
Number of warrants exercisable into common stock									4,100,000,000
Warrants exercise price									$ 0.0118
March 2017 Debentures [Member] \| Series A Warrants [Member]
Number of warrants exercisable into common stock									1,500,000,000
Warrants exercisable term									5 years
March 2017 Debentures [Member] \| Series B Warrants [Member]
Number of warrants exercisable into common stock									974,000,000
Warrants exercisable term									18 months
March 2017 Debentures [Member] \| Series C Warrants [Member]
Number of warrants exercisable into common stock									1,600,000,000
Warrants exercisable term									5 years
September 2017 Debentures [Member]
Number of warrants exercisable into common stock									6
Warrants exercise price									$ 9,016,133
September 2017 Debentures [Member] \| Series A Warrants [Member]
Number of warrants exercisable into common stock									2
Warrants exercisable term									5 years
September 2017 Debentures [Member] \| Series B Warrants [Member]
Number of warrants exercisable into common stock									2
Warrants exercisable term									18 months
September 2017 Debentures [Member] \| Series C Warrants [Member]
Number of warrants exercisable into common stock									2
Warrants exercisable term									5 years
Warrants [Member]
Number of warrants issued as anti-dilution provision									4,500,000,000	58,200,000
2007 Equity Plan [Member]
Stock option expense										$ 51,899
Weighted average period									5 years 4 months 13 days
Intrinsic value of options exercisable									$ 0	$ 0
Exchange Agreement [Member]
Number of shares issued upon conversion, value					$ 250,000
Exchange and Redemption Agreement [Member]
Gain on extinguishment of debt									$ 2,000,000
Series H Preferred Stock [Member]
Preferred stock shares authorized									14,202	14,202
Preferred stock par value									$ 0.01	$ 0.01
Preferred stock shares outstanding									10	10
Preferred stock, stated value									$ 1,000
Series F Convertible Preferred Stock [Member]
Preferred stock shares outstanding									1,750,000
Series F Convertible Preferred Stock [Member] \| Genomas, Inc [Member]
Number of common shares issued								1,750,000
Number of common stock issued, value								$ 174,097
Series L Convertible Preferred Stock [Member]
Preferred stock shares outstanding									250,000
Series M Preferred Stock [Member]
Preferred stock shares authorized									30,000	30,000	30,000
Preferred stock par value									$ 0.01	$ 0.01	$ 1,000
Preferred stock shares outstanding									22,000	0
Debt and accrued interest									$ 22,000,000
Debt description			Regardless of the number of shares of Series M Preferred Stock outstanding and so long as at least one share of Series M Preferred Stock is outstanding, the outstanding shares of Series M Preferred Stock shall have the number of votes, in the aggregate, equal to 51% of all votes entitled to be voted at any meeting of stockholders or action by written consent. Each outstanding share of the Series M Preferred Stock shall represent its proportionate share of the 51% allocated to the outstanding shares of Series M Preferred Stock in the aggregate.
Conversion rate			90.00%
Dividend rate			10.00%
Series M Preferred Stock [Member] \| Mr. Diamantis [Member]
Preferred stock, stated value		$ 0.01
Gain on extinguishment of debt		$ 18,800,000
Exchange of shares		22,000
Deemed dividend									3,200,000
Debt and accrued interest									$ 18,800,000
Series N Preferred Stock [Member]
Preferred stock shares authorized	50,000						50,000		50,000	50,000
Preferred stock par value	$ 1,000						$ 1,000		$ 0.01	$ 0.01
Preferred stock shares outstanding									29,434	0
Dividend rate	10.00%
Debt conversion description	The conversion price is equal to 90% of the lowest VWAP during the 10 trading days immediately prior to the conversion date. Holders of the Series N Preferred Stock are prohibited from converting Series N Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% (or, upon election of the holder, 9.99%) of the total number of shares of common stock then issued and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after notice to the Company.
Debt converted into shares									1,001
Series N Preferred Stock [Member] \| Exchange and Redemption Agreement [Member]
Number of common stock issued, value							$ 24,200,000
Series G Preferred Stock [Member]
Preferred stock, stated value										$ 1,000
Series G Preferred Stock [Member]
Weighted average common stock price percentage										85.00%
Number of shares issued upon conversion, value										$ 100
Series H Preferred Stock [Member]
Weighted average common stock price percentage									85.00%
Series K Preferred Stock [Member]
Preferred stock shares authorized									250,000	250,000
Preferred stock par value									$ 0.01	$ 0.01
Preferred stock shares outstanding									0	250,000
Series K Preferred Stock [Member] \| Exchange Agreement [Member] \| Alcimede LLC [Member]
Number of shares issued upon conversion, value				$ 250,000		$ 250,000
Cumulative dividends percentage						8.00%
Series J Preferred Stock [Member] \| Exchange Agreement [Member] \| Alcimede LLC [Member]
Number of shares issued upon conversion, value						$ 250,000
Series L Preferred Stock [Member]
Preferred stock shares authorized									250,000	250,000
Preferred stock par value									$ 0.01	$ 0.01
Preferred stock shares outstanding									250,000	0
Series L Preferred Stock [Member] \| Exchange Agreement [Member] \| Alcimede LLC [Member]
Number of shares issued upon conversion, value				$ 250,000
Series I-1 and Series I-2 Preferred Stock [Member] \| Exchange and Redemption Agreement [Member]
Preferred stock shares authorized	30,435.52						30,435.52
Number of common stock issued, value							$ 6,257,616
Deemed dividend									$ 3,700,000
Series I-2 Preferred Stock [Member]
Preferred stock shares outstanding	30,435.52						30,435.52
Number of common shares issued									313,000	940,075
Debt converted into shares									38,371,250
Number of shares converted									236.30	1,078.63
Number of shares issued for exercise of warrants										11,962